← Back to Patent Explorer
US5093361A Expired / Lapsed US ⏱️ 0.0 years remaining

D-2-(6-methoxy-2-naphthyl)-propionic acid and pharmaceutical compositions containing it

Assignee: Farma Resa Srl
•
Filing: 1990-02-26
•
Granted: 1992-03-03
•
Expires: 2010-02-26
📄 Original PDF 🌐 Google Patents 🔄 Sync Now

Abstract

Abstract The S-[d-2-(6-methoxy-2-naphthyl)-propionyl]d-2-mercaptopropionamidoacetic acid having formula: ##STR1## has improved therapeutic properties not only in comparison with the starting active principle, namely Naproxen, but also with respect to the corresponding racemic derivative, namely the (d,l) compound.

Inventors

  • 👤 Valentina Reiner
  • 👤 Caterina Sarda

Bibliographic Details

Application Number —
Jurisdiction US
Data Source google_patents
Last Synchronized 2026-11-06 08:56
CPC Classifications
C; C07; C07C; C07C327/00; C07C327/20; C07C327/32; A; A61; A61K; A61K31/00; A61K31/21; A61K31/265

Claims Analysis

Total Claims: 4
Claim 1
Independent Claim 29 words
A method for achieving anti-inflammatory and analgesic effect in a patient in need of such treatment which comprises administering to such patient an effective amount of S-d-2-mercaptopropionamido acetic acid.
Claim 2
Independent Claim 29 words
A method for achieving anti-inflammatory and analgesic effect in a patient in need of such treatment which comprises administering to such patient an effective amount of S-d-2-mercaptopropionamido acetic acid.
Claim 3
Dependent Claim 38 words
A pharmaceutical composition useful in achieving anti-inflammatory and analgesic effect in a patient and suitable for administration by oral, topical or rectal route which comprises an effective amount of S-d-2-mercaptopropionamido acetic acid and a pharmaceutically acceptable carrier therefor.
Claim 4
Dependent Claim 38 words
A pharmaceutical composition useful in achieving anti-inflammatory and analgesic effect in a patient and suitable for administration by oral, topical or rectal route which comprises an effective amount of S-d-2-mercaptopropionamido acetic acid and a pharmaceutically acceptable carrier therefor.

References Cited (Backward Citations)

EP0124925B1 Cited

USPTO Annuity & Maintenance Windows

Annuity Stage Window Opens Payment Deadline Surcharge Period Until Estimated Fee Status
3.5 Years (Year 4) 1995-03-03 1995-09-02 1996-03-03 $2000.00 Window Closed / Lapsed
7.5 Years (Year 8) 1999-03-03 1999-09-02 2000-03-03 $3760.00 Window Closed / Lapsed
11.5 Years (Year 12) 2003-03-03 2003-09-02 2004-03-03 $7700.00 Window Closed / Lapsed

Assigned Categories & Tags

No categories assigned to this patent yet.

Assign Category Tag